A phase II clinical study on the treatment of locally advanced esophageal cancer with SIB-IMRT combined with nitzumab

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027936

Enrollment

Unknown

Registered

2019-12-06

Start date

2019-12-20

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Combined treatment group:Simultaneous Integrated Boost combined with Nitzumab

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. esophageal squamous cell carcinoma patients confirmed by pathology; 2. distant metastasis excluded from baseline evaluation; 3. KPS >= 70; 4. patients' knowledge and understanding of the admission and the treatment to be accepted and sign the consent.

Exclusion criteria

Exclusion criteria: 1. Patients with drug allergy history; 2. Patients with abnormal liver and kidney function; 3. Patients with severe heart disease, psychosis, uncontrolled severe infection and active ulcer requiring treatment; 4. Previous history of malignant tumor or serious basic diseases that may affect the completion of treatment.

Design outcomes

Primary

Measure	Time frame
Treatment completion rate;Treatment related side effects;	—

Secondary

Measure	Time frame
The tumor regression rate;Local control rate;Overall survival rate;	—

Countries

China

Contacts

Public ContactHan Chun

The Fourth Hospital of Hebei Medical University

hanchun2006@126.com+86 13831105846

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026